Xconomy

AUGUST 17, 2016

and San Diego’s Avalon Ventures. Avalon Ventures founded Avelas, and has housed the startup with other Avalon biotech startups at its COI Pharmaceuticals R&D facility in San Diego. Avalon Ventures founder Kevin Kinsella plans to step down as a director of the company, along with Nikolay Savchuk of Torrey Pines Investment.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

AUGUST 31, 2016

In 2009, Tsien and Kevin Kinsella of Avalon Ventures founded San Diego’s Avelas Biosciences to develop fluorescent proteins that change color in the presence of cancer cells. In the statement released by UC San Diego, chancellor Pradeep Khosla said, every honor Tsien received was “justly deserved, and always received with humility.”.

San Diego 72

San Diego UCSD Avalon Study 72

Xconomy

JULY 20, 2016

Then came COI Pharmaceuticals , the shared “community of innovation” for startup biotechs established by San Diego’s Avalon Ventures as part of its partnership with GlaxoSmithKline. It’s a little like what Avalon is doing. We are definitely interested in oncology, but there is no value in disclosing details.”.

San Diego 40

San Diego Avalon Outsource Development Newsletter 40

Xconomy

JULY 10, 2016

It was during this time, she recalled, when Bock met Kevin Kinsella of San Diego’s Avalon Ventures. After talking with dozens of scientists, he would have a list of five or six names, and those were the people he would recruit for his startup. Larry and Kevin Kinsella had a really good partnership,” Diane Bock said. They had a lot of fun.”.

San Diego 40

San Diego Startup Avalon Venture Capital 40

Xconomy

SEPTEMBER 30, 2016

—Avalon Ventures led an $18 million Series A round for new cancer immunotherapy startup Fortis Therapeutics. . —Boston-based SQZ Biotech raised a $16 million Series B round to develop a broad range of cell therapies for cancer, and possibly infectious and autoimmune diseases as well.

Avalon 40

Avalon Thousand Oaks Study Startup 40

Xconomy

JULY 19, 2016

Existing investors Avalon Ventures and Correlation Ventures joined in the round. Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund.

San Diego 40

San Diego Avalon Research Examples 40

Xconomy

OCTOBER 30, 2016

To Walt Tendler, a consultant who has worked as the chief financial officer at San Diego-based Avalon Ventures and Mission Ventures, the proliferation of co-working spaces is making downtown San Diego “a really entrepreneur-friendly area. It’s really cool.”. Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 40

San Diego Incubator Avalon Mentor 40

Xconomy

MARCH 23, 2020

The coronavirus pandemic is narrowing the avenues open to biotechs for financing their endeavors, according to some industry veterans. “I I think that fear of losing out has pretty much gone out the window right now,” said Equillium (NASDAQ: EQ ) CEO Bruce Steel in a phone interview with Xconomy, speaking generally of investor appetite. “I

Invest 105

Invest San Diego Avalon Company 105

Xconomy

DECEMBER 7, 2018

Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.

Technology 98

Technology Develop Development San Diego 98

Xconomy

FEBRUARY 26, 2020

About three years ago fledgling San Diego-based startup PvP Biologics announced a $35 million deal with Takeda Pharmaceutical that gave the Japan pharma giant rights to acquire the company down the line. That day is here.

San Diego 72

San Diego Study Develop Development 72

Xconomy

SEPTEMBER 13, 2019

For decades, advanced lung cancer was a quick death sentence. That’s no longer a given, thanks in part to the arrival of immunotherapy. If a medical meeting in Barcelona this week was any indication, more help could be on the way.

Pricing 63

Pricing Help San Diego Avalon 63

Xconomy

APRIL 30, 2018

After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs , San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of interleukin-2, an anti-cancer drug of intense commercial interest in the 1980s.

Technology 78

Technology Venture Capital San Diego Avalon 78

Xconomy

NOVEMBER 14, 2018

Synthetic biology company Synthorx is laying plans for an initial public offering to raise money to advance its suite of enhanced cytokine drugs.

San Diego 76

San Diego Product Develop Development 76

Xconomy

JUNE 6, 2018

Awarepoint, the San Diego healthtech startup that specialized in real-time location systems for tracking medical equipment and people in hospitals and clinics, has gone 404. That’s the error code message that comes up for a website that no longer exists.

Tips 76

Tips San Diego Startup Avalon 76

Xconomy

AUGUST 30, 2017

Investment in experimental drugs for hearing loss, long an untapped field in the pharmaceutical industry, may be picking up, but drugs that actually help with these disorders remain elusive.

San Diego 59

San Diego Invest Help Develop 59

Xconomy

MAY 2, 2017

View the Slideshow In the not-too-distant future, a “planetary” computer will be able to create a computational model of your body, with the ability to run simulations of your health and to anticipate chronic disease before you show any symptoms.

San Diego 63

San Diego Technical Review Software Review Networking 63

Xconomy

MARCH 23, 2017

Xconomy is convening life sciences and technology founders, executives, investors, and entrepreneurs for an afternoon of fireside chats and solo talks at Human Impact of Innovation.

San Diego 52

San Diego Entrepreneur Technology Avalon 52

Xconomy

JANUARY 26, 2017

AnaptysBio is the first U.S. biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders.

Marketing 40

Marketing San Diego Invest Help 40